Biodefense Stocks Articles, Biodefense Stocks sector alerts and Q&A's
Q&A with Biodefense Company PositiveID (OTCBB: PSID); M-BAND and Firefly Status and Opportunity
New York, NY - September 4, 2013 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTC: PSID) a developer of biological detection and diagnostics solutions. Mr. William J. Caragol discusses the current status and opportunities for its lead technologies.
Biodefense Stock Q&A; PositiveID (OTCBB: PSID) Chairman and CEO Discusses New Firefly Dx Detection System
Point Roberts, WA - June 6, 2013 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and CEO of PositiveID Corporation (OTCBB: PSID) discussing the recent launch of the development of the Firefly Dx detection system.
Biodefense Stock Alert; Aethlon Medical (OTCBB: AEMD) Moves Following News on Contract
Point Roberts, WA - April 17, 2013 (Investorideas.com newswire) - Investorideas.com, an investor research portal specializing in sector research for independent investors including biodefense and homeland security stocks issues a trading alert for Aethlon Medical, Inc. (OTCBB: AEMD), trading at $0.1099, up 0.0070 6.80% 12:43PM EDT on over 688,000 shares.
Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Gains Over 21% in Morning Trading
Point Roberts, WA - January 24, 1013 (Investorideas.com Newswire) Investorideas.com, a leader in sector research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID).
Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Gains 40% on News
New York, NY - September 25, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID) trading up over 40% following news today.
Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Jumps up over 68%
New York, NY - September 4, 2012 - (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation(OTCBB: PSID), as the stock jumps over 68% in today's trading session.
Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Trading up
New York, NY - August 29, 2012 - (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID), trading up at $0.0135 , up 0.0010 or 8.00% 12:55PM EDT, trading up over 11% in earlier trading with a high of 0.0139 on over 500,000 shares in volume.
Homeland Defense Q&A Interview with PositiveID (OTCBB: PSID): How the M-BAND System Biothreat Detection is in the Running for BioWatch
New York, NY - July 23, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID) discussing its M-BAND System for biothreat detection.
Biotech Alert: PositiveID (OTCBB: PSID); Big Ambitions for Biodefense and Diabetes Markets for 2012
Chairman and CEO, Mr. William J. Caragol, Shares First Quarter Milestones for Small Company Aiming for Piece of the $3.1 Billion BioWatch Gen-3 Contract
New York, NY - April 4, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents its second exclusive Q&A interview with Medical technology stock, PositiveID Corporation (OTCBB: PSID). Mr. William J. Caragol, Chairman and Chief Executive Officer, illuminates on the first quarter operational highlights that have positioned the Company in the diabetes and biodefense markets for 2012.
Biodefense Stock News: Vista Partners Updates Coverage on PositiveID Corporation (OTCBB:PSID); $0.38 Target Price
SAN FRANCISCO - February 28, 2012 - (Investorideas.com Newswire) Vista Partners announced today that it has updated coverage on PositiveID Corporation (OTCBB: PSID) ("The Company" or "PSID"); and revised its twelve month target price to $0.38. Ross Silver, Principal Analyst at Vista Partners stated, "The Company's MicroFluidic Systems subsidiary is attempting to secure a portion of the $3.1B Homeland Defense BioWatch pathogen detection contract.
Biodefense Stocks to Watch in 2012; PositiveID (OTCBB:PSID) and Northrop Grumman (NYSE: NOC) Opportunities with BioWatch
New York, NY - February 24, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an investor snapshot of Homeland Security and Biodefense stocks , PositiveIDCorporation (OTCBB: PSID) and Northrop Grumman (NYSE: NOC), two potentially qualified biodetector systems suppliers for BioWatch Gen-3.
Biodefense Stock News: PositiveID (OTCBB:PSID) to Present M-BAND at ASM Biodefense and Emerging Diseases Research Meeting February 26-29
The Boeing Company (NYSE:BA) , Hamilton Sundstrand and MicroFluidic Systems to Jointly Exhibit M-BAND at 10th Annual American Society for Microbiology Conference
DELRAY BEACH, Fla., February 21, 2012 - (Investorideas.com Newswire) PositiveID Corporation's (OTCBB: PSID) subsidiary MicroFluidic Systems ("MFS"), a developer of molecular diagnostic systems, announced today it will present its M-BAND (Microfluidics-based Bioagent Autonomous Networked Detector) system at the 10 th Annual American Society for Microbiology ("ASM") Biodefense and Emerging Diseases Research Meeting, to be held February 26-29, 2012, in Washington, DC at the Omni Shoreham Hotel.
Q&A Interview with Medical Technology Stock PositiveID (OTCBB: PSID)
New York, NY - February 16, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Medical technology stock, PositiveIDCorporation (OTCBB: PSID).
More - Read archived news and articles
Defense stocks Indices and ETF's
- PHLX DEFENSE SECTOR INDEX (Philadelphia: ^DFX)
- S&P Sector Indices Brochure
- Standard and Poor's 500 Aerospace & Defense Index is a capitalization-weighted index. The index was developed with a base level of 10 for the 1941-43 base period. This is a GICS level 4 sub-industry group. The parent index is SPX. This is a GICS Level 4 Sub-Industry group.
- The Amex Defense Index (DFI) is an equal dollar weighted Index designed to represent a cross section of widely held, highly capitalized companies involved in providing systems, equipment and services to the United States government and its allies for the purpose of supporting military, defense and intelligence efforts. The component stocks operate in industry segments that include, but are not limited to, military aircraft manufacturing, shipbuilding, ground transportation, aerospace instrumentation and technology, specialized communication and radar systems, ammunition and weapon systems.
- The iShares Dow Jones U.S. Aerospace & Defense Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Dow Jones U.S. Select Aerospace & Defense Index.
- The SPADE Defense Index (AMEX: DXS) is a modified market cap-weighted index that was developed to provide a financial benchmark for the performance of companies involved with the defense, homeland security, and space. More than 50 companies currently comprise the index. Information on the Index -- including its methodology, rules, constituents, and performance -- can be found at http://www.spadeindex.com. In October 2005, the first (and currently only) exchange traded fund on defense and homeland security was launched by Powershares. The Powershares Aerospace & Defense Portfolio ETF trades under the symbol 'PPA' and is designed to track the performance of the SPADE. - more info
Biodefense Stocks - Top News Story
Investing Ideas: Biodefense Stocks to Watch
Point Roberts, WA - May 3, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biodefense stocks issues the following update of publicly traded companies in the sector to watch.
National Homeland Security Newswire
Tech Alert: The Wocket and COIN Set the Stage for Changing Your Wallet as You Know It
(Mon, 9 Dec 2013 06:00:00 PST)
Point Roberts, WA, NEW YORK, NY - December 9, 2013 (NHSK Newswire) Investorideas.com, an investor news and research portal specializing in leading sectors including biometrics and mobile technology issues an exclusive interview with Mr. Gino Pereira, Chief Executive Officer of NXT-ID, Inc (OTCQB: NXTD) and Mr. Kanishk Parashar, CEO of Coin.
Biometric Stock Alert: New smartphones using FPC fingerprint technology launched by Pantech in Korea
(Fri, 6 Dec 2013 06:00:00 PST)
Source: Fingerprint Cards AB - December 6, 2013 (NHSK newswire) During December and January, the three Pantech Android phone models IM-A900S, IM-A900K and IM-A900L, Vega Secret Up, will start to sell in operator stores all over Korea.
PPSS Group Launch Slash Resistant Homeland Security Base Layers
(Wed, 4 Dec 2013 06:00:00 PST)
Knaresborough, United Kingdom - December 4, 2013 (NHSK newswire) New type of slash resistant base layers have been launched today by PPSS Group after identifying that prison and correctional officers all over the world operate within an environment where such realistic and clear risks and threat have been identified.
Biodefense Stock to Watch
PharmAthene, Inc. (NYSE Amex: PIP)
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
- SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
- Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
- rBChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246 - a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA earns $40 million in net profits from sales of ST-246). www.PharmAthene.com.
Biodefense Stocks Directory
Cepheid (NASDAQ: CPHD) Cepheid, based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.
Ceragenix Phamaceuticals Inc. (OTCBB: CGXP) Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins™ or CSAs for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin and Cerashield products are currently in the developmental stage.
Cerus Corporation (NASDAQ:CERS) Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The Company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.
Cleveland BioLabs, Inc. (NasdaqCM: CBLI) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.
Combimatrix (Nasdaq:CBMX) CombiMatrix is a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. We make the arrays using our patented in situ electrochemical synthesis process, which provides the ability to easily change array content to stay current with new developments and to meet the evolving needs of our customers. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. We have also developed the capabilities of producing arrays that utilize bacterial artificial chromosomes on our arrays, also enabling genetic analysis. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory.
Commonwealth Biotechnologies, Inc. (NASDAQ:CBTE) CBI is a growing contract research organization that offers a comprehensive, integrated range of services for the discovery and development of therapeutics, vaccines and diagnostics by working as a partner with its customers in the global life sciences industries. Applying skills from its extensive experience serving life sciences companies worldwide, CBI offers insight, innovation and project management capabilities to customers, whether pharmaceutical giants or emerging biotechnology companies. CBI operates through four business units: (1) CBI Services, a discovery-phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business; and (4) Venturepharm Asia, Beijing, China, a contract research joint venture specializing in process scale-up, formulation development, cGMP manufacturing and clinical trial management. CBI companies directly employ over 100 staff in three laboratories and have access to over 2,000 additional staff through CBI's Venturepharm ( Asia) joint venture.
View the full Biodefense Stocks directory
View the full Homeland Defense/ Defense Stocks directory as a member or in pdf
Biodefense Stock and Industry News from Google News
Wed, 11 Dec 2013 05:37:37 GMT